Patents by Inventor Eugene Lukanidin
Eugene Lukanidin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9683032Abstract: Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumor progression and/or in inducing tumor metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.Type: GrantFiled: October 29, 2013Date of Patent: June 20, 2017Assignee: Cancer Research Technology LimitedInventors: Jorg Klingelhöfer, Noona Ambartsumian, Mariam Grigorian, Eugene Lukanidin
-
Publication number: 20160159888Abstract: Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumour progression and/or in inducing tumour metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.Type: ApplicationFiled: October 29, 2013Publication date: June 9, 2016Inventors: Jorg Klingelhöfer, Noona Ambartsumian, Mariam Grigorian, Eugene Lukanidin
-
Publication number: 20070010433Abstract: The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment diagnosis and/or prognosis of an invasive disease. The invention features the compounds selected from the group comprising antisense compounds derived from the sequence of SEMA3E and/or sema3E, peptide compounds derived from the sequence of said semaphorins, anti-bodies against said semaphorins, and peptide compounds derived from the sequence of Plexin A receptor. Furthermore, the invention provides methods for prognosis and/diagnosis of malignancy of cancer based of estimation of the levels of expression and proteolytic processing of said semaphorins in a sample of a tissue or body fluid. The invention also concerns a method for producing an attractant polypeptide by establishing a cleavage product of SEMA3E. and/or sema3E.Type: ApplicationFiled: July 10, 2003Publication date: January 11, 2007Applicant: SEMA APSInventors: Morten Albrechtsen, Claus Christensen, Eugene Lukanidin, Ole Olsen
-
Patent number: 6903188Abstract: The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.Type: GrantFiled: February 12, 2001Date of Patent: June 7, 2005Assignee: Prolifia Inc.Inventors: Eugene Lukanidin, Elisabeth Marianne Bock, Vladimir Berezin
-
Patent number: 6638504Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 MRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as tseful model systems for in vitro and in vivo anti-metastasis drug screening.Type: GrantFiled: April 23, 1999Date of Patent: October 28, 2003Assignee: Research Corporation Technologies, Inc.Inventor: Eugene Lukanidin
-
Publication number: 20030100503Abstract: The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.Type: ApplicationFiled: October 11, 2002Publication date: May 29, 2003Inventors: Eugene Lukanidin, Elisabeth Marianne Bock, Vladimir Berezin
-
Publication number: 20020172680Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 MRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodie4 directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.Type: ApplicationFiled: April 29, 2002Publication date: November 21, 2002Inventor: Eugene Lukanidin
-
Publication number: 20020169110Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 MRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodie4 directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as tseful model systems for in vitro and in vivo anti-metastasis drug screening.Type: ApplicationFiled: February 5, 2002Publication date: November 14, 2002Inventor: Eugene Lukanidin
-
Publication number: 20020099010Abstract: The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.Type: ApplicationFiled: February 12, 2001Publication date: July 25, 2002Inventors: Eugene Lukanidin, Elisabeth Marianne Bock, Vladimir Berezin
-
Publication number: 20010011126Abstract: The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.Type: ApplicationFiled: September 10, 1999Publication date: August 2, 2001Inventors: ELISABETH MARIANNE BOCK, VLADIMIR BEREZIN, EUGENE LUKANIDIN
-
Patent number: 5965360Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Assignee: Research Corporation Technologies, Inc.Inventors: Sayeeda Zain, Eugene Lukanidin
-
Patent number: 5843686Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 1998Assignee: Research Corporation Technologies, Inc.Inventors: Sayeeda Zain, Eugene Lukanidin
-
Patent number: 5801142Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.Type: GrantFiled: June 6, 1995Date of Patent: September 1, 1998Assignee: Research Corporation Technologies, Inc.Inventors: Sayeeda Zain, Eugene Lukanidin
-
Patent number: 5798257Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.Type: GrantFiled: January 31, 1994Date of Patent: August 25, 1998Assignee: Research Corporation Technologies, Inc.Inventors: Sayeeda Zain, Eugene Lukanidin